Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Status:
Completed
Trial end date:
2018-09-21
Target enrollment:
Participant gender:
Summary
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic
dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately
controlled with topical treatments.